College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Department of Pediatrics, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
Medicine (Baltimore). 2022 Dec 23;101(51):e32359. doi: 10.1097/MD.0000000000032359.
Diabetic kidney disease (DKD) is one of the common complications of diabetes, the most crucial cause of end-stage renal disease, and a significant cause of death in diabetes patients. In recent years, Xuefu Zhuyu decoction has also been widely used in treating diabetic nephropathy. However, there need to be more systematic reviews that comprehensively describe the effectiveness and safety of Xuefu Zhuyu decoction in treating DKD. Therefore, we will conduct a systematic review and meta-analysis to evaluate the indicators of Xuefu Zhuyu decoction in the treatment of DKD to provide evidence-based support.
Eligible published randomized controlled trials from January 2005 to October 2022 will be obtained by searching PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, Wanfang, and VIP in Chinese and English. The Cochrane Collaboration Risk of bias tool will be used for methodological quality assessment and risk of bias. The meta-analysis will be performed using Cochrane RevMan 5.4 software.
This study will compare the following indicators: the primary outcomes: urinary albumin excretion rate and urea nitrogen. Secondary outcomes: blood creatinine; 24 hours urine protein quantification; glycosylated hemoglobin; fasting blood glucose; 2-hour postprandial blood glucose; total cholesterol; triglycerides; total effective rate; incidence of adverse events.
The results of this systematic review will provide an objective, evidence-based basis for judging the efficacy and safety of Xuefu Zhuyu decoction in treating DKD.
糖尿病肾病（DKD）是糖尿病的常见并发症之一，是终末期肾病的最关键病因，也是糖尿病患者死亡的重要原因。近年来，血府逐瘀汤也被广泛用于治疗糖尿病肾病。然而，需要有更系统的综述来全面描述血府逐瘀汤治疗 DKD 的疗效和安全性。因此，我们将进行系统评价和荟萃分析，以评估血府逐瘀汤治疗 DKD 的指标，为提供循证支持。
通过检索 PubMed、Cochrane Library、EMBASE、Web of Science、CNKI、万方和维普等中英文数据库，获取 2005 年 1 月至 2022 年 10 月发表的随机对照试验。采用 Cochrane 协作风险偏倚工具进行方法学质量评估和风险偏倚评估。使用 Cochrane RevMan 5.4 软件进行荟萃分析。
本研究将比较以下指标：主要结局：尿白蛋白排泄率和尿素氮。次要结局：血肌酐；24 小时尿蛋白定量；糖化血红蛋白；空腹血糖；餐后 2 小时血糖；总胆固醇；甘油三酯；总有效率；不良反应发生率。
本系统评价的结果将为判断血府逐瘀汤治疗 DKD 的疗效和安全性提供客观、循证的依据。
